Noctiva

Polyuria, Nocturia, Polydipsia + 14 more

Treatment

17 Active Studies for Noctiva

What is Noctiva

Desmopressin

The Generic name of this drug

Treatment Summary

Desmopressin (dDAVP) is a medication used to treat conditions that cause an excessive amount of urine, such as nocturnal enuresis, nocturia, and diabetes insipidus. It is a synthetic form of a pituitary hormone that helps regulate the body’s water content. Desmopressin is more effective and has fewer side effects than the natural hormone and is available in various forms such as nasal spray, intravenous solution, tablets, and lyophilized oral tablets. It was approved by the FDA in 2018 for the treatment of nocturia in adults. The active ingredient

Ddavp

is the brand name

image of different drug pills on a surface

Noctiva Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Ddavp

Desmopressin

1978

101

Effectiveness

How Noctiva Affects Patients

Desmopressin is a drug that acts similarly to a natural hormone in the body (antidiuretic hormone or ADH) to reduce the amount of urine produced. It also increases the amount of factor VIII activity in patients with hemophilia and von Willebrand's disease type I. Desmopressin is less likely to cause an increase in blood pressure when compared to ADH, and intranasal administration of desmopressin produces effects that are about one-tenth as powerful as those from an equivalent dose administered by injection.

How Noctiva works in the body

Desmopressin binds to special receptors in the cells that line the kidneys' tubes. This triggers a chain reaction inside the cells, which causes more water channels to be opened in the cell membrane. This makes it easier for water to move in and out of the cell.

When to interrupt dosage

The suggested dose of Noctiva depends on the detected condition, such as Minor Surgical Procedures, Pituitary Gland and Surgery, Hemophilia A. The dosage depends on the technique of delivery featured in the table below.

Condition

Dosage

Administration

Nocturia

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Spray, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous

Polydipsia

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Spray, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous

von Willebrand Disease

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Spray, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous

Hemophilia A

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Spray, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous

Pituitary Diseases

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Spray, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous

Uremia

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Spray, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous

Hemorrhage

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Spray, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous

von Willebrand Disease

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Spray, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous

Hemorrhage

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Spray, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous

Hemophilia A

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Spray, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous

Diabetes Insipidus, Neurogenic

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Spray, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous

Pituitary Surgery

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Spray, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous

Polyuria

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Spray, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous

Nocturnal Enuresis

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Spray, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous

Minor Surgical Procedures

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Spray, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous

Polyuria

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Spray, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous

Hemophilia A

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Spray, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous

Warnings

Noctiva has three contraindications and should not be utilized if you experience any of the conditions given in the table below.

Noctiva Contraindications

Condition

Risk Level

Notes

Hyponatremia

Do Not Combine

Renal Insufficiency

Do Not Combine

Hyponatremia

Do Not Combine

There are 20 known major drug interactions with Noctiva.

Common Noctiva Drug Interactions

Drug Name

Risk Level

Description

1-benzylimidazole

Minor

The risk or severity of hypertension can be increased when Desmopressin is combined with 1-benzylimidazole.

2,5-Dimethoxy-4-ethylamphetamine

Minor

The risk or severity of hypertension can be increased when Desmopressin is combined with 2,5-Dimethoxy-4-ethylamphetamine.

2,5-Dimethoxy-4-ethylthioamphetamine

Minor

The risk or severity of hypertension can be increased when Desmopressin is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.

4-Bromo-2,5-dimethoxyamphetamine

Minor

The risk or severity of hypertension can be increased when Desmopressin is combined with 4-Bromo-2,5-dimethoxyamphetamine.

4-Methoxyamphetamine

Minor

The risk or severity of hypertension can be increased when Desmopressin is combined with 4-Methoxyamphetamine.

Noctiva Toxicity & Overdose Risk

The lowest toxic amount of desmopressin for humans is 0.3 µg/kg/10M. Overdosing on this drug can lead to low sodium levels in the body, which can cause seizures, confusion, drowsiness, irregular heartbeat, and swelling. If an overdose is suspected, reduce the dose or frequency of administration, or stop use if necessary. Additionally, it is recommended to check sodium levels in the blood and start medical treatment if needed.

image of a doctor in a lab doing drug, clinical research

Noctiva Novel Uses: Which Conditions Have a Clinical Trial Featuring Noctiva?

30 active trials are currently investigating the potential of Noctiva to alleviate Polyuria, Hemophilia A and Hemophilia B.

Condition

Clinical Trials

Trial Phases

Pituitary Diseases

0 Actively Recruiting

Hemorrhage

0 Actively Recruiting

Pituitary Surgery

0 Actively Recruiting

von Willebrand Disease

5 Actively Recruiting

Phase 3, Phase 1, Phase 2

Hemophilia A

2 Actively Recruiting

Phase 3, Phase 1

Uremia

0 Actively Recruiting

Nocturia

3 Actively Recruiting

Phase 4, Not Applicable

Polyuria

0 Actively Recruiting

Minor Surgical Procedures

0 Actively Recruiting

von Willebrand Disease

0 Actively Recruiting

Polydipsia

0 Actively Recruiting

Diabetes Insipidus, Neurogenic

3 Actively Recruiting

Phase 1, Early Phase 1

Hemophilia A

0 Actively Recruiting

Polyuria

0 Actively Recruiting

Hemorrhage

0 Actively Recruiting

Hemophilia A

0 Actively Recruiting

Nocturnal Enuresis

4 Actively Recruiting

Phase 3, Not Applicable

Noctiva Reviews: What are patients saying about Noctiva?

3.7

Patient Review

9/20/2018

Noctiva for Urination During the Night

Noctiva does work, however the cure is worse than the ailment. The drainage from this medicine is incredibly painful and unpleasant tasting. I thought it might get easier to use after time, but I finally gave up. It's like spraying liquid cayenne pepper up your nose. I would rather get up to pee a half dozen times than go through that pain again."

2.3

Patient Review

9/22/2018

Noctiva for Urination During the Night

I recently started using this nasal spray, and was very disappointed. It burns terribly and causes my nose to run incessantly. My eyes water nonstop for about twenty minutes after using it. I don't think I'll be continuing to use this product.

2

Patient Review

1/31/2019

Noctiva for Urination During the Night

The application of this treatment is unfortunately quite painful, making it suboptimal to use right before bed. That said, the treatment itself is effective.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about noctiva

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Noctiva discontinued?

"Avadel will no longer be marketing Noctiva as of February 7th, 2019. This is due to the product's links to Nocturnal Polyuria (a condition involving overproduction of urine at night) in adults. There is also a risk of hyponatremia."

Answered by AI

Is Noctiva a prescription drug?

"Noctiva is a prescription medication used in adults who wake up 2 or more times during the night to urinate due to nocturnal polyuria, a condition where your body makes too much urine at night. Noctiva was not studied in patients younger than 50 years of age."

Answered by AI

What is Noctiva used for?

"Noctiva is a medication meant to treat nocturia, or having to wake up at night to urinate, in adults who have to do so at least twice a night. This is caused by nocturnal polyuria, which is defined as producing urine at night that makes up more than a third of your daily urine production."

Answered by AI

How much does Noctiva cost?

"Noctiva nasal spray is around $453 for a supply of 3.8 grams."

Answered by AI

Clinical Trials for Noctiva

Image of Massachusetts General Hospital in Boston, United States.

Norethindrone Acetate-Ethinyl Estradiol for Oxytocin Deficiency

7 - 21
All Sexes
Boston, MA

An open-labeled, interventional pilot trial, 10 youth with AVP-D and 10 PD matched for age, sex, and BMI will be recruited from Pediatric Endocrinology and Neuroendocrinology at Massachusetts General Hospital and in the community. This study tests the hypothesis that oral estrogen/progestin will stimulate endogenous oxytocin release in control subjects. Eligible participants will receive two tablets in a single administration containing a total of 1 mg of norethindrone acetate 70 mcg of ethinyl estradiol. Sampling for blood and saliva will take place at baseline and approximately 24 hours following study drug administration. Neuropsychological assessment (anxiety, mood and emotion regulation; impulse control; aberrant eating behaviors; social cognition and functioning; quality of life) will be assessed at baseline to characterize the study population.

Phase < 1
Recruiting

Massachusetts General Hospital

Elizabeth A Lawson, MD

Have you considered Noctiva clinical trials?

We made a collection of clinical trials featuring Noctiva, we think they might fit your search criteria.
Go to Trials
Image of Children's Hospital Los Angeles in Los Angeles, United States.

Timed Awakening for Bedwetting

6 - 17
All Sexes
Los Angeles, CA

The goal of this clinical trial is to evaluate the effectiveness of nightly timed awakening in the treatment of nocturnal enuresis in children aged 6-17. The main questions it aims to: * Determine feasibility of nightly timed awakenings * Determine the role, if any, of comorbidities on resolution of enuresis * Determine incidence of daytime accidents * Obtain patient and parental satisfaction scores Researchers will compare a control group to treatment groups to see if there is any impact on nocturnal enuresis. Participants will be woken up by parents in the middle of the night to use the restroom. In addition, participants will receive 30 minute psychotherapy sessions using telehealth.

Waitlist Available
Has No Placebo

Children's Hospital Los Angeles

Evalynn Vasquez, MD

Image of Massachusetts General Hospital in Boston, United States.

Norethindrone Acetate-Ethinyl Estradiol for Oxytocin Deficiency

18 - 65
All Sexes
Boston, MA

This is an open-label, pilot study, to characterize oxytocin response to a single dose of oral Estrogen-progestin in patients with arginine-vasopressin deficiency compared to healthy controls. The association between oxytocin levels and measures of psychopathology (i.e., anxiety and depression) and quality of life across groups will be examined. We hypothesize that: 1. Salivary and blood oxytocin response to Estrogen-progestin will be lower in arginine-vasopressin deficiency compared to healthy control. 2. Lower salivary and blood oxytocin levels will be associated with more severe symptoms of anxiety, depression, and social emotional difficulties as well as lower quality of life.

Phase < 1
Recruiting

Massachusetts General Hospital

Elizabeth A Lawson, MD

Have you considered Noctiva clinical trials?

We made a collection of clinical trials featuring Noctiva, we think they might fit your search criteria.
Go to Trials

Have you considered Noctiva clinical trials?

We made a collection of clinical trials featuring Noctiva, we think they might fit your search criteria.
Go to Trials